All In Biotech

Drug Trial Radar · NCT05840822

Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of CBD TPM Capsules in Adults for Use in the Reduction of Insomnia Severity

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 519 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

519

Planned (sponsor's estimate)

Start

May 16, 2024

Primary completion

Sep 30, 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Avecho BiotechnologyIndustry
Sponsor type
Industry
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Insomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep. Consequences of insomnia include daytime sleepiness, poor memory function, decline in concentration with negative impacts on social and work activities. Although medical cannabis and cannabis products are widely used worldwide for the management of symptoms associated with insomnia, there is little clinical data available to support the efficacy or utility of CBD in the management of sleep disorders. The proposed study will assess whether nightly doses of 75mg or 150mg of an 8 week period are able to improve patient reported sleep quality when compared to a placebo.

Conditions

  • Insomnia

Interventions

  • Cannabidiol (CBD) Capsule 75mgDrug

    Cannabidiol (CBD) capsule containing 75mg CBD

  • PlaceboDrug

    Placebo capsule without cannabidiol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from study baseline of insomnia severity index (ISI) score at 8 weeksTime frame: 8 weeks
  2. Mean change from study baseline in subject sleep efficiency (sSE) at 8 weeksTime frame: 8 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Pioneer Clinical Research

    North Sydney, New South Wales, Australia

  • Key Health, CBD South

    Sydney, New South Wales, Australia

  • Griffith University

    Southport, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Captain Stirling Medical Centre

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.